The rules governing THC beverages are changing faster than most brands can track. Federal agencies, Congress, and individual states are all moving simultaneously, often in opposite directions. This page is our attempt to keep it all in one place. We update it as developments happen.
Last updated: July 21, 2026
The single most consequential date on the calendar for hemp-derived THC beverages is November 12, 2026.
On November 12, 2025, President Trump signed P.L. 119-37, a government spending bill that quietly rewrote the federal definition of hemp. Section 781 replaces the old delta-9-only standard with a total THC measurement (including THCA and delta-8) and sets two caps for finished products: 0.4 milligrams of total THC per container for most hemp-derived cannabinoid products, and 10 milligrams per container for beverages specifically. These limits take effect exactly 365 days after signing, on November 12, 2026.
The beverage cap is more lenient than the general cap, but it's still a category killer for most products on the market. A hemp seltzer at 5mg per can is legal today. On November 13, that same can needs to be at or below 10mg per container to survive, and even that assumes the "container" definition holds at the individual can level. The FDA still hasn't clarified what "container" means (more on that below).
There is no grace period. There is no sell-through safe harbor. Non-compliant products become Schedule I controlled substances overnight.
The provision was inserted by Senator Mitch McConnell in a must-pass spending bill with no public hearings and no industry notice. The U.S. Hemp Roundtable estimates it would eliminate approximately 95% of currently available hemp-derived cannabinoid products, threatening $28.4 billion in economic activity and over 300,000 jobs.
No legislation has passed to delay or modify the November 12 date. The House passed its 2026 Farm Bill on April 30 without any hemp delay amendments. Hemp amendments were ruled "not germane" during markup and withdrawn before reaching the floor. The Senate Farm Bill, not yet introduced as of this writing, is the last realistic legislative vehicle.
Section 781 required the FDA to publish three lists within 90 days (by February 10, 2026): all cannabinoids naturally produced by Cannabis sativa, all THC-class cannabinoids, and all other cannabinoids with similar effects. It also required the FDA to clarify what "container" means. None of this has been delivered. The industry is being asked to comply with a law whose key terms remain undefined by the agency responsible for defining them.
Working backward from November 12 through a typical 60-90 day manufacturing and distribution cycle, the last viable purchase orders for conversion-grade CBD biomass go out in July or August 2026. Biomass purchasing is already freezing. The clock isn't really four months. For manufacturers and distributors, it's already here.
Multiple bills are competing to either delay the cliff, replace it with a regulatory framework, or blow past it entirely. None has passed. Here's where they stand.
Rep. Andy Barr (R-KY) filed the LPHA as an amendment to the House Farm Bill on May 28, 2026, after withdrawing an earlier version in April. It's a "regulate, don't ban" framework:
The Barr Bill has not been introduced as a standalone bill and has no bill number. Barr is reportedly working with the White House on revised language. It represents the most comprehensive "regulate like alcohol" framework on the table, but it has no legislative vehicle at the moment.
Rep. Beth Van Duyne (R-TX) began circulating a draft bill in mid-June 2026 that would create a federal carve-out specifically for hemp-derived THC beverages. Key provisions:
This bill is notable for two reasons. First, it only saves beverages, not edibles, gummies, tinctures, or any other hemp-derived THC products. Second, it came from an unexpected source: a mainstream conservative Republican from the Dallas-Fort Worth suburbs with no prior association with cannabis policy. The bill has not been formally introduced and has no bill number.
Senators Ron Wyden and Jeff Merkley, both Oregon Democrats, introduced the CSRA with specific per-serving caps: 5mg THC per serving and 50mg per package for edibles, topicals, and inhalables, with a lower limit of 5mg per serving and 10mg per package for beverages. This is the closest Senate-side companion to the Barr approach, though the frameworks differ significantly in how they assign regulatory authority.
Several bills would simply push the November 12 date without replacing the framework:
None of these has advanced past introduction.
On April 23, 2026, Acting Attorney General Todd Blanche issued a final order moving two categories of cannabis from Schedule I to Schedule III, effective immediately:
This was not a blanket rescheduling. Adult-use (recreational) cannabis remains Schedule I. The result is a split classification that creates its own set of complications.
The DEA launched a separate administrative hearing to consider rescheduling all marijuana, including recreational, from Schedule I to Schedule III. The hearing ran 13 business days before Chief Administrative Law Judge Derek Julius, from June 29 to July 15, 2026.
Seven designated opposition parties testified, all of them anti-rescheduling groups. No pro-rescheduling advocacy organizations were permitted to participate as designated parties. Despite this structural disadvantage for the rescheduling side, observer accounts suggest the opposition underperformed. Harvard's Dr. Bertha Madras, the opposition's marquee expert witness, reportedly acknowledged under cross-examination that cannabis meets Schedule III's statutory criteria. A sheriff called by opposing states conceded that regulated cannabis markets can assist law enforcement and that most diversion comes from unlicensed operators.
Post-hearing briefs are due August 17, 2026. After that, the ALJ issues a non-binding recommendation, and DEA leadership decides whether to accept, modify, or reject it. A final rule would face immediate court challenges. Realistic timeline for full rescheduling: late 2026 at the earliest, more likely 2027.
Tax relief (the big one): Section 280E of the tax code prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, resulting in effective tax rates above 70%. With medical cannabis now Schedule III, qualifying operators can claim standard deductions. Treasury guidance applies this retroactively to January 1, 2026 for calendar-year taxpayers.
What it doesn't change: Federal trademark registration is still uncertain. Interstate commerce is still restricted. Banking access remains limited. Adult-use businesses are still subject to 280E until recreational cannabis is rescheduled.
Multiple lawsuits have been filed challenging the April 23 order, consolidated in the D.C. Circuit:
Arguments include procedural deficiencies, the major questions doctrine, and treaty obligations. The House Appropriations Subcommittee also approved a funding rider that would block DOJ from spending money on rescheduling, though it hasn't been enacted.
On July 16, 2026, Senator Cory Booker reintroduced the Cannabis Administration and Opportunity Act (S. 5022), which would remove cannabis from the Controlled Substances Act entirely. 17 Democratic co-sponsors, including Schumer and Wyden. No Republicans. This is the third time the CAOA has been introduced, and it is unlikely to pass in a Republican-controlled Senate.
What makes it worth watching for hemp beverage brands: the bill includes a provision that would prevent the November 12 hemp recriminalization. Even if the broader descheduling push doesn't move, that provision could surface as language in other vehicles.
Executive Order 14370, "Increasing Medical Marijuana and Cannabidiol Research," was signed December 18, 2025. It directed:
The CMS pilot launched April 1, 2026 and was immediately challenged in court. Smart Approaches to Marijuana filed suit arguing CMS bypassed required notice-and-comment rulemaking. A temporary restraining order was denied, and the pilot continues while litigation proceeds.
What the EO doesn't do: It does not delay, modify, or override the November 12 hemp cliff. It explicitly calls on Congress to act. The EO signals White House support for the hemp industry but stops short of the executive action that would actually change the timeline.
Every brand in the THC beverage space is operating on a regulatory surface that could shift in any direction before the end of the year. Here's the honest assessment:
If you're hemp-only: The November 12 cliff is existential unless Congress acts. The Senate Farm Bill is the last realistic vehicle for a delay or regulatory framework. Multiple competing proposals exist, but none has advanced. Building a business plan on "Congress will fix it" is a bet, not a strategy.
If you're cannabis-licensed: Schedule III for medical cannabis is real and the tax relief is significant. Broader rescheduling for recreational is likely but not guaranteed, and the timeline is uncertain. The split classification creates operational complexity that will persist for at least another year.
If you're building dual-channel capability: You're in the strongest position regardless of outcome. A cannabis license provides regulatory stability. Hemp provides market reach where state law permits. The brands that survive the next year will be the ones that aren't dependent on a single framework.
The regulatory environment for THC beverages is the most complex and fast-moving in the consumer products industry. Nobody, including us, can predict where it lands. What we can do is track it in real time, build distribution infrastructure that works across both channels, and help brands make informed decisions with current information rather than assumptions about what Congress might do.
We'll update this page as developments happen. If you want to talk through how any of this affects your specific situation, reach out.
This page is for informational purposes and does not constitute legal advice. Consult qualified legal counsel for guidance specific to your business.
CannaBev Distribution handles regulatory complexity so brands can focus on growth. Manufacturing, compliance, and multi-channel distribution through a single partnership.